West Haven, CT – According to filings with the U.S. Securities and Exchange Commission, Normunity is raising $65,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Rachel Humphrey played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Normunity
Normunity, Inc., is a biotechnology company creating a new class of precision immuno-oncology medicines, called immune normalizers, that target novel mechanisms that free the bodys normal immunity against cancer. Based on an ongoing, interactive academic-biotech alliance with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is targeting newly-discovered mechanisms of immune disruption in cancer based on proprietary discovery platforms that elucidate the complex interactions between human cancer and the immune system. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. Normunity is located in Boston, Mass. and West Haven, Conn.

To learn more about Normunity, visit http://www.normunity.com/

Contact:
Rachel Humphrey, Chief Executive Officer
203-993-6580

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved